“This is not a sausage factory”
Lundbeck’s science chief regrets having to halt the development of candidate drug desmoteplase after having spent more than DKK 1 billion. But the group knew it was a high-risk endeavor all along, he says.
BY STEFAN SINGH KAILAY
Lundbeck announced recently that it would be shelving the further development of candidate drug desmoteplase against ischemic stroke, adding that the decision would lead to a write-down of DKK 309 million in the current quarter.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck stalls on important decision
For abonnenter
